Vinpocetine-AKOS - instructions for use, dose, side effects, contraindications

Improves the metabolism of the brain, increasing the intake of glucose and oxygen by brain tissue. Increases the resistance of neurons to hypoxia; enhances the transport of glucose to the brain,through the blood-brain barrier; translates the process of the decay of glucose into an energetically more economical, aerobic pathway; selectively blocks Ca ²⁺ -dependent phosphodiesterase; increases the levels of adenosine monophosphate (AMP), cyclic guanosine monophosphate (cGMP) and adenosine triphosphate (ATP) of the brain. Increases the exchange of norepinephrine and serotonin of the brain; stimulates the ascending branch of the noradrenergic system, has an antioxidant effect. Reduces platelet aggregation and increased blood viscosity; increases the deforming ability of erythrocytes and blocks the utilization of adenosine by red blood cells; helps to increase the oxygen release of red blood cells. Increases cerebral blood flow; reduces the resistance of cerebral vessels without a significant change in the indices of the systemic circulation. Does not have the effect of "stealing" and enhances blood supply, especially in ischemic areas of the brain. Penetrates through the placental barrier.

Pharmacokinetics:

Quickly absorbed. Time to reach the maximum concentration in blood plasma - 1 hour. Absorption occurs mainly in the proximal parts of the gastrointestinal tract.When passing through the wall of the intestine is not exposed to metabolism. The maximum concentration in the tissues is noted 2-4 hours after ingestion. Communication with proteins - 66%, bioavailability with ingestion - 7%. Clearance 66.7 l / h, exceeds the plasma volume of the liver (50 l / h), which indicates extrahepatic metabolism. At repeated receptions the kinetics has linear character. The half-life in humans is 4.83 ± 1.29 hours. It is excreted by the kidneys and through the intestine in a ratio of 3: 2.

Indications:

- a decrease in the severity of neurological and mental symptoms in various forms of cerebral circulatory insufficiency (including the recovery stage of ischemic or hemorrhagic stroke, the consequences of a stroke, transient ischemic attack, vascular dementia, vertebrobasilar insufficiency, cerebrovascular atherosclerosis, posttraumatic and hypertensive encephalopathy);

- chronic vascular diseases of the choroid and retina;

- hearing loss perceptive type, Meniere's disease, idiopathic tinnitus.

Contraindications:

- acute phase of hemorrhagic stroke, severe ischemic heart disease, severe arrhythmias, hypersensitivity to any of the components of the drug.

- pregnancy (possibly placental bleeding and spontaneous abortion, probably as a result of increased placental blood supply).

- lactation period (with the drug should stop breastfeeding).

- children under 18 years (due to insufficient data).

Dosing and Administration:

Inside, after eating, 3 times a day. The initial daily dose is 15 mg. The maximum daily dose is 30 mg. Duration of treatment up to 3 months, with kidney or liver disease, the drug is prescribed in the usual dose.

Before cancellation, the dose should be gradually reduced.

Side effects:

From the cardiovascular system: ECG change (segment depression ST, lengthening the interval QT); tachycardia, extrasystole, lability of blood pressure, sensation of hot flashes.

From the central nervous system: sleep disturbances (insomnia or increased drowsiness), dizziness, headache.

On the part of the digestive system: dry mouth, nausea, heartburn.

Other: allergic skin reactions, general weakness, increased sweating.

Overdose:

Symptoms: increased severity of side effects.

Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.

Interaction:

Interactions are not observed with simultaneous use with p-blockers (chloranolol, pindolol), clopamid, glibenclamide, digoxin, acenocoumarol and hydrochlorothiazide, imipramine.

The simultaneous use of vinpocetine and a-methyl-dopa sometimes caused some strengthening of the hypotensive effect, so this treatment requires regular monitoring of blood pressure.

Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution when concurrently administering with the drugs central, antiarrhythmic and anticoagulant action.

Special instructions:

Presence of the syndrome of the prolonged interval QT and taking medications that cause lengthening of the interval QT, requires periodic ECG monitoring. In case of lactose intolerance, it should be taken into account that lactose is included in the formulation. Data on the effect of vinpocetine on the ability to drive a car and perform work that requires speed of psychomotor reactions is not.

Form release / dosage:

Tablets 5 mg.

Packaging:

For 10, 20, 25 tablets in a contour mesh package.

1,2,5 contour mesh packages with instructions for use in a pack of cardboard.

330 contour cell packs of 10 tablets, 45 outline cell packs of 25 tablets with instructions for use in cardboard boxes (for hospitals).

Storage conditions:

List B. In a dry, protected from light place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:

2 years. Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N001925 / 02

Date of registration:23.07.2008

The owner of the registration certificate:SYNTHESIS, OJSC SYNTHESIS, OJSC Russia

Manufacturer: & nbsp

SYNTHESIS, OJSC Russia

Representation: & nbspSYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products SYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products Russia

Information update date: & nbsp22.09.2015

Illustrated instructions

Instructions

Vinpocetin-AKOS (Vinpocetine-AKOS)